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Although the oxidative stress frequently occurs in patients with chronic hepatitis C, its role in future hepatocellular carcinoma (HCC)
development is unknown. Hepatic 8-hydroxydeoxyguanosine (8-OHdG) was quantified using liver biopsy samples from 118 naı ¨ve
patients who underwent liver biopsy from 1995 to 2001. The predictability of 8-OHdG for future HCC development and its relations
to epidemiologic, biochemical and histological baseline characteristics were evaluated. During the follow-up period (mean was
6.7±3.3 years), HCC was identified in 36 patients (30.5%). Univariate analysis revealed that 16 variables, including 8-OHdG counts
(65.2±20.2 vs 40.0±23.5 cells per 10
5mm
2, Po0.0001), were significantly different between patients with and without HCC. Cox
proportional hazard analysis showed that the hepatic 8-OHdG (P¼0.0058) and fibrosis (P¼0.0181) were independent predicting
factors of HCC. Remarkably, 8-OHdG levels were positively correlated with body and hepatic iron storage markers (vs ferritin,
Po0.0001 vs hepatic iron score, Po0.0001). This study showed that oxidative DNA damage is associated with increased risk for
HCC and hepatic 8-OHdG levels are useful as markers to identify the extreme high-risk subgroup. The strong correlation between
hepatic DNA damage and iron overload suggests that the iron content may be a strong mediator of oxidative stress and iron
reduction may reduce HCC incidence in patients with chronic hepatitis C.
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Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide, and the death rate due to this tumour has
been increasing over the past 20–30 years in the Unites States
(El-Serag, 2002) and in Japan (Nishioka et al, 1991). Chronic infection
with hepatitis C virus (HCV) has been recognised as an increased risk
of HCC; approximately 20% of HCV-infected individuals have
diseases that progress to cirrhosis, and about 40% of these patients
develop HCC after a mean of 10–15 years (Seeff, 2002). Consequently,
surveillance programmes based on periodic ultrasound examination
and serum a-fetoprotein determination are recommended for patients
with chronic hepatitis C. However, the effectiveness of these protocols
has not been fully assessed and they afford no contribution to
improvement of clinical outcomes in patients with chronic hepatitis C
(Gebo et al, 2002). Therefore, it is desirable to establish a useful
marker that could identify cases at high risk of developing HCC
among chronic HCV-infected patients.
Although the mechanisms underlying HCC development during
chronic HCV infection have been widely investigated, they are still
unclear. It has been reported that structural and nonstructural
proteins of HCV, such as Core and NS3, play a role in cell
transformation, using in vitro cell culture systems (Sakamuro et al,
1995; Ray et al, 1996) and transgenic animals (Moriya et al, 1998).
But whether expression of HCV protein(s) directly induces HCC in
chronic HCV-infected patients is unknown. Recently, it has been
assumed that oxidative stress may be relevant to this process of
HCV-induced carcinogenesis, as has been suggested in several
other malignancies (Kasai, 1997). Considerable data suggest that
reactive oxygen species (ROS) may play a pathogenic role in
carcinogenesis (Crawford and Cerutti, 1985). The most damaging
species among the many ROS is the hydroxyl radical. The hydroxyl
radical has been shown to be responsible for a number of base
modifications that include thymine glycol, thymidine glycol
(Cathcart et al, 1984), 5-(hydroxylmethyl)uracil (Hollstein et al,
1984), and also 8-hydroxydeoxyguanosine (8-OHdG) (Shigenaga
et al, 1989; Kasai, 1997). 8-Hydroxydeoxyguanosine is a modifica-
tion of guanine that induces a point mutation in the daughter
DNA strands (Kuchino et al, 1987; Shibutani et al, 1991) and it is
therefore used as a marker of oxidatively generated DNA damage
in several diseases (Shigenaga et al, 1989; Kasai, 1997). In patients
with chronic hepatitis C, increased 8-OHdG in DNA extracted from
liver tissue was also reported (Shimoda et al, 1994; Mahmood et al,
2004; Fujita et al, 2007). These reports suggest that oxidative stress
may be involved in the progression of liver disease, but they
showed no direct participation of oxidative stress in hepato-
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scarcinogenesis in the liver of HCV-infected patients. Also, no
information is available on whether ROS-mediated damage to
DNA is useful for prediction of HCC development in chronic
hepatitis C patients.
In view of these considerations, we have examined the influence
of the degree of ROS-mediated hepatic DNA damage as measured
by counts of 8-OHdG immunohistochemically positive hepatocyte
nuclei on the prevalence of future HCC development in chronic
HCV-infected patients. Moreover, we evaluated the relation of the
degree of ROS-mediated DNA damage with the epidemiologic,
biochemical, and histological findings in chronic hepatitis C.
PATIENTS AND METHODS
Patients with chronic hepatitis C
This study comprised 118 consecutive patients (66 males and 52
females; mean age 55.8±10.8 years) recruited between January
1995 and October 2001 with HCV-related chronic hepatitis
(Table 1). All patients fulfilled the following inclusion criteria:
(1) liver injury caused by chronic HCV infection. All patients had
persistently elevated serum alanine aminotransferase (ALT) levels
and were seropositive for both anti-HCV antibody (the third-
generation enzyme-linked immunosorbent assay; Ortho Diagnostic
Systems, Raritan, NJ, USA) and HCV-RNA (Amplicor-HCV assay;
Roche Molecular Diag. Co., Tokyo, Japan). (2) Liver biopsy. Liver
tissue was obtained by percutaneous needle biopsy in all patients
for diagnostic purposes. (3) Follow-up without interferon (IFN)-
based therapy. The follow-up consisted of monthly blood tests and
monitoring of tumour markers at the outpatients clinic of our
department, and ultrasonography and dynamic computed tomo-
graphy were performed at regular intervals. As it is known that IFN
treatment reduces the incidence of HCC in patients with chronic
hepatitis C (Nishiguchi et al, 1995), patients with a history of
previous IFN-based treatment were excluded from the study. None
of them had received any antiviral therapy during the follow-up
period.
Exclusion criteria were as follows: a family history of
haemochromatosis; haemolytic disease; serological markers for
hepatitis B virus (HBV) (hepatitis B surface antigen and hepatitis B
core antibody); or human immunodeficiency virus infection.
Patients with concurrent diseases or those taking medications
that may interfere with free radical production, such as
nonsteroidal anti-inflammatory drugs, vitamins and iron-contain-
ing drugs, were excluded from the study. Patients with chronic
alcohol consumption of ethanol in excess of 40gday
 1 for male
and 20gday
 1 for female for at least 5 years were also excluded. All
patients had no HCC or other cancers, by an initial screening
examination. Informed consent was obtained from each patient
and the study was approved by the Ethical Committee of Mie
University. The study was carried out according to the ethical
guidelines of the 1975 Declaration of Helsinki.
Clinical parameters were obtained for each patient at the time of
liver biopsy: age; sex; body mass index; duration of HCV infection
(when contamination was very probable and a precise data;
transfusion or drug addiction in the past year); alcohol intake;
biochemical, haematological, iron-related, and virological serum
markers; and liver histological findings and 8-OHdG immunor-
eactivity.
The diagnosis of HCC was made by several imaging methods
(ultrasonography, dynamic computed tomography, arteriography,
or magnetic resonance imaging) and confirmed histologically in 22
cases. Time to HCC occurrence was defined as the interval between
the date of liver biopsy and the detection of tumour, death without
HCC occurrence, or the last examination until 31 October 2006. All
patient deaths were considered end points irrespective of cause of
death. The mean follow-up period was 6.7±3.3 (range, 0.4–11.8)
years.
Histological evaluation
All of the liver biopsy samples were stained with haematoxylin–
eosin and Masson’s trichrome, and were graded for the degree of
necroinflammatory activity and staged for the extent of fibrosis
using the criteria of Desmet et al (1994). The histological
quantification of hepatic iron was carried out according to
Deugnier et al (1992) by scoring iron separately within hepatocytes
(hepatic iron score, 0–36), sinusoidal cells (sinusoidal iron score,
0–12), and portal tracts or fibrotic tissue (portal iron score, 0–12)
using liver samples stained with Perls’ Prussian blue. The total iron
score (TIS, 0–60) was defined by the sum of these scores. This
score has been shown to highly correlate with the biochemical
hepatic iron index and hepatic iron concentration as measured by
the atomic absorption spectrophotometry in patients with chronic
liver diseases (Piperno et al, 1998; Silvia et al, 2005).
Immunohistochemical study
Immunohistochemical staining of 8-OHdG was performed as
previously described (Fujita et al, 2007). Mouse monoclonal
antibody against 8-OHdG (Japanese Aging Control Institute,
Shizuoka, Japan) and Alexa 488-labelled goat antibody against
mouse IgG (Molecular Probes, Eugene, OR, USA) were used. The
degree of immunoreactivity was estimated by counting the number
of stained hepatocyte nuclei using Adobe Photoshop version 5.5
and NIH Image free software (Vers. 1.62, National Institute of
Health, image program).
Statistical analysis
Results were expressed as mean±s.d. or median. Comparisons
between groups were performed using the Mann–Whitney U-test
or Kruskal–Wallis test for continuous variables and the w
2 or
Fisher’s exact test for categorical data. Correlation coefficients
between numerical variables were calculated as Spearman’s rank
test. Cumulative HCC incidence curves were determined using the
Kaplan–Meier method and the differences between groups were
Table 1 Baseline characteristics of patients with chronic hepatitis C
Characteristics Chronic hepatitis C (N¼118)
Age (years) 55.8±10.8 (57.5)
Gender (M/F) 66/52
Laboratory data
ALT (IUl
 1) 73.5±53.4 (58.0)
AST (IUl
 1) 70.1±41.8 (61.5)
Platelet count ( 10
4mm
 3) 14.9±5.9 (14.6)
Serum HCV-RNA (kIUml
 1)( N¼89) 1570±1240 (1420)
HCV genotype (1a/1b/2a/2b) (N¼60) 0/53/5/2
Liver histology
Inflammatory activity (0/1/2/3)
a 1/41/49/27
Fibrosis staging (0/1/2/3/4)
b 1/29/26/27/35
Total iron score
c 7.75±5.80 (7.00)
8-OHdG-positive hepatocytes
(per 10
5mm
2)
48.4±26.2 (42.5)
Data are expressed as mean±s.d. (median). ALT¼alanine aminotransferase;
AST¼aspartate aminotransferase; HCV¼hepatitis C virus; 8-OHdG¼8-hydro-
xydeoxyguanosine.
aInflammatory activity was graded according to the intensity of
necroinflammatory lesions: 0, no histological activity; 1, mild activity; 2, moderate
activity; 3, severe activity.
bFibrosis staging was scored as follows: 0, no fibrosis; 1,
portal fibrosis without septa; 2, portal fibrosis with few septa; 3, numerous septa
without cirrhosis; 4, cirrhosis.
cThe histological quantification of iron was assessed by
total iron score proposed by Deugnier et al (1992).
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sassessed with the log-rank test. Cox proportional hazard regression
analysis was used to identify significant factors that influence
future HCC development. All tests were two-tailed, and P-values
less than 0.05 were considered as statistically significant. Statistical
analyses were performed using the SPSS 11.5 software (SPSS Inc.,
Chicago, IL, USA).
RESULTS
In situ detection of 8-OHdG-positive hepatocytes using
biopsy samples
In the liver of patients with chronic hepatitis C, 8-OHdG
immunoreactivity was strongly observed in the nuclei (weakly in
the cytoplasm) of hepatocytes, Kupffer cells, and infiltrated
lymphocytes (Figure 1A). The hepatocyte nuclei were differen-
tiated from the nuclei of other cells using computed analyses at the
point of nuclear shape and size. The number of 8-OHdG-positive
hepatocytes in patients with chronic hepatitis C was counted from
7 to 123 cells per 10
5mm
2, the median being 42.5 cells per 10
5mm
2.
Using the liver samples of patients with simple fatty liver as
controls, immunoreactivity of 8-OHdG was faintly observed in the
nuclei of hepatocytes in this experimental setting (Figure 1B). The
specificity of the anti-8-OHdG antibody used in this study was
confirmed by several parallel experiments. Sections in which the
primary antibody was omitted or those treated with normal
control serum instead of the primary 8-OHdG antibody consis-
tently yielded negative staining. Localisation of 8-OHdG was
considered specific because the recognition of hepatocytes was
completely blocked by previous incubation with 25ngml
 1 of
8-OHdG, but not by over a thousand-fold greater concentration of
guanosine. Further, enzymatic treatment with RNase did not affect
the immunoreaction of oxidised DNA.
Analysis of factors associated with the occurrence of HCC
in patients with chronic hepatitis C
Until the end of follow-up (mean was 6.7±3.3 years), HCC
occurrence was identified in 36 patients (30.5%) in this study.
Seven patients died with no sign of HCC. The overall cumulative
incidence of HCC was 3.4, 12.0, 17.2, and 38.9% at 1, 3, 5, and 10
years, respectively. To examine the effect of degree of liver
oxidative DNA damage on HCC development during chronic HCV
infection, clinical variables, including hepatic 8-OHdG quantifica-
tion, were compared between patients who developed HCC and
those who did not develop (non-HCC group) during the follow-up
(Table 2). No significant difference was found in the patient age,
body mass index, alcohol consumption, serum albumin levels, red
blood cell count, and HCV genotype distribution between patients
with and without HCC. In the group of patients with HCC, the
proportion of male subjects, duration of infection, serum ALT,
aspartate aminotransferase (AST), total bilirubin, hyaluronic acid,
haemoglobin, iron, transferrin saturation, and ferritin levels at
liver biopsy were significantly higher, and HCV-RNA titres and
platelet count were significantly lower, than in the group of
PA
A
B
Figure 1 8-Hydroxydeoxyguanosine immunohistochemical staining in
liver tissue from chronic hepatitis C and control (simple fatty liver) patients.
(A) In the liver of chronic hepatitis C patient, 8-OHdG immunoreactivity
was strongly observed throughout the whole acinus (PA¼portal area) and
mainly in the nuclei of hepatocytes and Kupffer cells (arrows in (A)). (B)I n
the liver of control (simple fatty liver), immunoreactivity of 8-OHdG was
weak in the nuclei of hepatocytes. Scale bar, 100mmi n( A) and (B).
Table 2 Comparison of epidemiologic and clinical variables of patients
who developed HCC and patients who remained free of HCC during the
follow-up period
Characteristics
HCC group
(N¼36)
Non-HCC
group
(N¼82) P-value
Age (years) 57.3±8.2 54.7±11.4 0.3718
a
Gender (M/F) 26/10 40/42 0.0182
b
Body mass index (kgm
 2) 23.6±3.5 24.1±3.2 0.6657
a
Duration of HCV infection (years)
(N¼58)
31.7±10.5 26.9±9.8 0.0463
a
Alcohol intake (gday
 1) 21.0±37.0 21.2±38.9 0.6221
a
Laboratory data
ALT (IUl
 1) 91.9±50.4 65.6±52.9 0.0021
a
AST (IUl
 1) 91.4±42.7 60.5±38.3 0.0003
a
Serum albumin (gdl
 1) 3.65±0.40 3.75±0.45 0.1235
a
Total bilirubin (mgdl
 1) 0.96±0.29 0.75±0.88 o0.0001
a
Hyaluronic acid (ngml
 1) 206±138 132±151 0.0003
a
Platelet count ( 10
4mm
 3) 11.7±4.5 16.4±5.8 o0.0001
a
Red blood cell count ( 10
4mm
 3) 429±48 418±50 0.1993
a
Haemoglobin (gdl
 1) 13.9±1.3 13.2±1.6 0.0302
a
Serum iron (mgdl
 1) 151±68 121±62 0.0320
a
Transferrin saturation (%) 45.7±22.6 36.2±20.0 0.0289
a
Serum ferritin (ngml
 1) 264±158 151±149 0.0002
a
Serum HCV-RNA (kIUml
 1)
(N¼89)
844±900 1720±1260 0.0068
a
HCV genotype (1a/1b/2a/2b)
(N¼60)
0/5/2/0 0/48/3/2 0.1100
b
Liver histology
Inflammatory activity (0/1/2/3)
c 0/4/18/14 1/37/31/13 0.0015
b
Fibrosis staging (0/1/2/3/4)
d 0/1/3/10/22 1/28/23/17/
13
o0.0001
b
Total iron score
e 11.09±4.75 6.23±5.62 o0.0001
a
8-OHdG-positive hepatocytes
(per 10
5mm
2)
65.2±20.2 40.0±23.5 o0.0001
a
Data are expressed as mean±s.d. HCC¼hepatocellular carcinoma; ALT¼alanine
aminotransferase; AST¼aspartate aminotransferase; HCV¼hepatitis C virus; 8-
OHdG¼8-hydroxydeoxyguanosine.
aMann–Whitney U-test.
bFisher’s exact test,
otherwise w
2 test.
cInflammatory activity was graded according to the intensity of
necroinflammatory lesions: 0, no histological activity; 1, mild activity; 2, moderate
activity; 3, severe activity.
dFibrosis staging was scored as follows: 0, no fibrosis; 1,
portal fibrosis without septa; 2, portal fibrosis with few septa; 3, numerous septa
without cirrhosis; 4, cirrhosis.
eThe histological quantification of iron was assessed by
total iron score proposed by Deugnier et al (1992).
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spatients without HCC during the follow-up. The histological
grading and staging scores were significantly higher in the HCC
group than in the non-HCC group. The prevalence of hepatic iron
deposits in patients with HCC was also significantly greater than
that in non-HCC patients. Hepatic 8-OHdG expression levels in
patients who developed HCC were significantly higher than in
those who did not develop HCC (65.2±20.2 vs 40.0±23.5 positive
cells per 10
5mm
2, Po0.0001; Mann–Whitney U-test) (Figure 2).
When hepatic steatosis was evaluated by scoring system as 0, no
steatosis; 1, o33% of hepatocytes with steatosis; 2, 33–66% of
hepatocytes affected; 3, 466% of hepatocytes affected, the degree
of steatosis was not significantly different between HCC and non-
HCC groups.
To examine the independent factors that affect the development
of HCC, Cox proportional hazard regression analysis was
performed using the 16 variables that were significantly different
between HCC and non-HCC groups by univariate analyses. The
multivariate analysis identified two factors as independent factors
for HCC development: degree of hepatocytic 8-OHdG immuno-
reactivity (odds ratio, 1.487 (each 10 positive cells per 10
5mm
2
increase); P¼0.0058) and histological staging (odds ratio, 4.090
(each stage 1 increase); P¼0.0181) (Table 3). When the patients
were stratified according to the degree of hepatic 8-OHdG counts
and histological fibrosis staging, the cumulative incidence of HCC
was significantly increased in proportion to these variables (long-
rank test) (Figure 3A and B). The cumulative incidences of HCC of
3, 5, and 10 years were 0, 0, and 0% in 8-OHdG counts of o25
(cells per 10
5mm
2) subgroup (n¼23), 4.4, 11.1, and 21.8%
in 25–50 (cells per 10
5mm
2) subgroup (n¼45), 14.2, 14.2, and
84.9% in 50–75 (cells per 10
5mm
2) subgroup (n¼29), and 38.8,
55.5, and 74.6% in 475 (cells per 10
5mm
2) subgroup (n¼21),
respectively.
Correlation between hepatocytic 8-OHdG counts and
clinical characteristics in patients with chronic hepatitis C
To estimate the cause of hepatic oxidative DNA damage,
correlation of clinical findings with hepatic 8-OHdG levels was
evaluated (Table 4). The age of patients, body mass index, duration
of infection, alcohol consumption, and the serum HCV-RNA titre
were not related to the degree of oxidative DNA damage.
8-Hydroxydeoxyguanosine immunoreactivity was significantly
higher in male than in female patients. Serum transaminases,
platelet count, histological inflammation grade, and fibrosis stage
were significantly correlated with the hepatic 8-OHdG levels. It is
noteworthy that the hepatic 8-OHdG levels were strongly and
positively correlated with body and hepatic iron deposition
markers; serum ferritin levels and the hepatic iron deposit grade,
that is, TIS, were strongly correlated with hepatic 8-OHdG count
(8-OHdG vs ferritin, r¼0.640, Po0.0001; vs TIS, r¼0.768,
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Figure 2 Comparison between 8-OHdG counts in patients who
developed HCC (N¼36) and those who remained free of HCC (non-
HCC, N¼82) during the follow-up period. Baseline 8-OHdG counts were
significantly higher in the HCC group than in the non-HCC group in
patients with chronic hepatitis C.
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Figure 3 Cumulative incidence of HCC in 118 patients with chronic
hepatitis C. Incidence curves were determined using the Kaplan–Meier
method and statistical analysis was performed using the long-rank test. (A)
Cumulative incidence of HCC divided by degrees of hepatic 8-OHdG
expression levels. (B) Cumulative incidence of HCC divided by degrees of
histological hepatic fibrosis staging score.
Table 3 Factors associated with the occurrence of HCC in patients with
chronic hepatitis C by Cox proportional hazard regression analysis
Factor Odds ratio 95% CI P-value
Count of 8-OHdG-positive hepatocytes
(each 10 cells per 10
5mm
2 increase)
1.487 1.12–1.97 0.0058
Fibrosis staging (each stage 1 increase) 4.090 1.27–13.15 0.0181
HCC¼hepatocellular carcinoma; 8-OHdG¼8-hydroxydeoxyguanosine; CI¼confidence
interval.
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sPo0.0001) (Table 4 and Figure 4). These results suggest the
association between hepatic 8-OHdG production and iron deposi-
tion in the liver of patients with chronic hepatitis C.
DISCUSSION
Although free radicals are normally produced by many reactions
essential for cell metabolism and energy production, they are also
implicated in the pathogenesis of several different diseases (Valko
et al, 2007). Reactive oxygen species production within the cells is
controlled by numerous antioxidant intracellular defence mechan-
isms, but under certain conditions, ROS overproduction exceeds
the cellular defences and damages cell components including
nucleic acids (Valko et al, 2007). Reactive oxygen species attack on
DNA causes the production of stable covalent bonds and the
subsequent formation of DNA adducts, such as 8-OHdG (Shigen-
aga et al, 1989). Experiments in which DNA templates containing
8-OHdG were used indicated that this oxidatively modified DNA
residue can induce G-C to T-A transversion at DNA replication
(Kuchino et al, 1987; Shibutani et al, 1991), suggesting that the
lesion is mutagenic and therefore potentially carcinogenic, but the
role of this oxidative DNA adduct in human carcinogenesis is not
entirely understood.
Chronic HCV infection is recognised as the most major risk
factor for HCC (Nishioka et al, 1991; El-Serag, 2002; Seeff, 2002),
but little is known about the precise role of HCC development in
HCV-related liver disease. It was reported recently that oxidative
damage is a peculiar feature of HCV-mediated liver injury. Patients
with chronic hepatitis C showed increased oxidative stress markers
in serum or in the liver (Shimoda et al, 1994; Sumida et al, 2000;
Mahmood et al, 2004; Fujita et al, 2007). Therefore, we measured
the amount of 8-OHdG in liver biopsy specimen of patients with
chronic hepatitis C and examined its relation with future HCC
development. Baseline clinical variables were compared between
patients with and without HCC development. Based on univariate
analysis, the following numerous variables were picked up for
potential factors for HCC development: (1) gender and duration of
infection, (2) hepatic inflammation (serum ALT and AST levels
and histological grade), (3) hepatic fibrosis (hyaluronic acid,
platelet count, and histological stage), (4) iron-related markers
(haemoglobin, serum iron, transferrin saturation, ferritin, and
TIS), (5) serum HCV-RNA titres, and (6) hepatocytic 8-OHdG
Table 4 Correlations between clinical findings and 8-OHdG levels in the
liver of patients with chronic hepatitis C (N¼118)
Statistics
Characteristics
Hepatic 8-OHdG levels
(positive cells per 10
5lm
2) rP -values
Age (years) 0.149
a 0.1059
a
Gender
Male (N¼66) 57.7±23.3 o0.0001
b
Female (N¼52) 36.7±22.4
Body mass index (kgm
 2) 0.073
a 0.4271
a
Duration of HCV infection
(years) (N¼58)
0.237
a 0.0677
a
Alcohol intake (gday
 1) 0.121
a 0.2709
a
Laboratory data
ALT (IUl
 1) 0.541
a o0.0001
a
AST (IUl
 1) 0.605
a o0.0001
a
Platelet count
( 10
4mm
 3)
 0.430
ao0.0001
a
Serum ferritin (ngml
 1) 0.640
a o0.0001
a
Serum HCV-RNA
(kIUml
 1)( N¼89)
 0.197
a 0.0721
a
Inflammatory activity
c
A0 or A1 (N¼42) 32.2±21.2
A2 (N¼49) 52.3±22.6 o0.0001
d
A3 (N¼27) 62.4±26.0
Fibrosis staging
e
F0 or F1 (N¼30) 26.6±14.7
F2 (N¼26) 46.0±22.1 o0.0001
d
F3 (N¼27) 52.4±21.2
F4 (N¼35) 66.3±26.3
Total iron score
f 0.768
a o0.0001
a
Data are expressed as mean±s.d. 8-OHdG¼8-hydroxydeoxyguanosine;
HCV¼hepatitis C virus; ALT¼alanine aminotransferase; AST¼aspartate amino-
transferase.
aSpearman rank correlation test.
bMann–Whitney U-test.
cInflammatory
activity was graded according to the intensity of necroinflammatory lesions: 0, no
histological activity; 1, mild activity; 2, moderate activity; 3, severe activity.
dKruskal–
Wallis test.
eFibrosis staging was scored as follows: 0, no fibrosis; 1, portal fibrosis
without septa; 2, portal fibrosis with few septa; 3, numerous septa without cirrhosis; 4,
cirrhosis.
fThe histological quantification of iron was assessed by total iron score
proposed by Deugnier et al (1992).
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Figure 4 Correlations between hepatic 8-OHdG staining and serum ferritin levels (A), and TIS in hepatic tissues (B), in 118 patients with chronic
hepatitis C.
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scounts. Cox proportional hazard analysis identified increased
hepatic oxidative DNA damage, together with histological fibrosis,
which is a well-recognised risk factor for HCC (Greten et al, 2005),
as an independent risk factor for HCC development. This result
suggests that the hepatic oxidative stress plays an important role
in hepatocarcinogenesis and it may be a useful marker to predict
future HCC development in chronic HCV-infected patients.
Especially in the group of patients with hepatic 8-OHdG counts
exceeding 75 positive cells per 10
5mm
2, the HCC incidence during
the first 3 years was extremely high (38.8%) (Figure 3A), indicating
that these patients constitute a very high-risk subgroup for
developing HCC and should necessarily be carefully monitored
by several modalities. Recently, Maki et al (2007) evaluated the
expression levels of 8-OHdG of non-cancerous hepatic tissues in
HCV-infected patients who developed HCC and received curative
tumour resection. The postoperative cumulative HCC-free survival
was significantly shorter in patients with the highest percentage of
8-OHdG-positive hepatocytes, indicating that the hepatic 8-OHdG
levels are also useful for prediction of HCC recurrence in patients
with chronic HCV infection who developed HCC.
Several additional risk factors for HCC were identified in
patients with chronic hepatitis C in previous reports – increased
age (Seeff, 2002), heavy alcohol intake (Donato et al, 1997), and
chronic coinfection with HBV (Donato et al, 1997) – but our
results did not identify these factors for HCC. This may be
attributable to the fact that our study population excluded heavy
alcohol abusers (defined as a chronic consumer of ethanol in
excess of 40gday
 1 for male and 20gday
 1 for female for at least 5
years) and included relatively old patients (median age was 57.5
years). Patients coinfected with HBV were completely excluded
from our study because all patients were seronegative for both
hepatitis B surface antigen and hepatitis B core antibody. Recently,
several reports have suggested that persons with diabetes mellitus
are at an increased risk for developing HCC (El-Serag et al, 2001),
and obesity, which frequently accompanies diabetes, has also been
reported to increase the risk for hepatic steatosis and HCC in
HCV-infected patients (Ohata et al, 2003). But, body mass index
and hepatic steatosis were not significantly different between the
HCC- and non-HCC-developed groups among our patients.
To determine the factors involved in the occurrence of hepatic
oxidative stress during chronic HCV infection, epidemiologic,
laboratory, and histological variables were examined for associa-
tion with hepatocytic 8-OHdG staining counts. Quantitative
analysis revealed that hepatocytic 8-OHdG levels were significantly
correlated with serum aminotransferase levels and with the
histological grading of necroinflammation, suggesting a possible
link between hepatic oxidative stress and hepatic inflammation in
chronic hepatitis C. It is unclear whether oxidative stress is the
cause or the consequence of liver injury, but it has been
demonstrated that oxidative stress can directly activate Kupffer
cells, causing the release of inflammatory and profibrogenic
cytokines such as tumour necrosis factor-a and transforming
growth factor-b (Poli and Parola, 1997). Accordingly, the
hepatocytic 8-OHdG counts were also significantly correlated with
hepatic fibrosis, as assessed by the serum hyaluronic acid, platelet
count, and histological staging score. Sumida et al (2000) have also
shown a significant association between oxidative stress (serum
thioredoxin levels) and hepatic fibrosis (hyaluronic acid, type IV
collagen-7S domain, procollagen-III peptide) in HCV-positive
persons, suggesting that ROS is an important cofactor in
accelerating the development of hepatic fibrosis during chronic
HCV infection, which may lead to further acceleration of HCC
development. In addition, the hepatic 8-OHdG levels were
significantly correlated with the serum ferritin and hepatic iron
amounts assessed by TIS, suggesting a strong relationship between
the damage to hepatocytic DNA and body store of iron in chronic
hepatitis C patients. It is known that free iron promotes generation
of oxygen radicals by catalysing the Fenton reaction in which Fe
2þ
reacts with H2O2 to generate highly reactive OH
K radicals, which
can cause nucleic acid damage and 8-OHdG adducts. Therefore,
iron may cause liver tissue injury by increasing the formation of
toxic hydroxyl radicals leading to progression of liver inflamma-
tion, fibrosis, and increased risk for developing liver cancer during
chronic HCV infection. Increased iron stores were associated with
increased oxidative DNA damage, suggesting that removing iron
stores in the body, for example by phlebotomy (Yano et al, 2004),
or dietary iron restriction (Iwasa et al, 2004), which has been
accepted as a useful treatment option, may delay or reduce the
incidence of HCC in patients with chronic hepatitis C. Additional
studies are warranted to determine whether these iron-reduction
therapies are effective for reducing HCC and for improving the
clinical outcomes of patients with chronic HCV infection.
In conclusion, this study clearly showed that in patients with
chronic hepatitis C, the oxidative DNA damage in the liver
frequently occurred and that it was strongly associated with
increased risk for HCC. Strong positive correlations between
hepatic oxidative stress and iron overload suggest that iron content
may be a mediator of hepatic oxidative stress and that iron
reduction may be beneficial to reduce the HCC incidence in
chronic HCV-infected patients.
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